TcLand Expression signs a licensing agreement with Inserm Transfert

Strategic collaboration on the development of companion diagnostic tests for rheumatoid arthritis therapies

08-Jul-2010 - France

TcLand Expression SA announced the signature of a licensing agreement with Inserm Transfert. The terms of the agreement include the grant of worldwide, exclusive licenses to TcLand Expression for two different patents covering gene expression signatures which can predict responsiveness to rheumatoid arthritis (RA) therapies.

TcLand Expression is developing and clinically validating gene-expression-based biomarkers in the field of transplantation and companion diagnostic tests for use with auto-immune disease therapies. Based on the methods protected by the two Inserm patents, TcLand Expression intends to develop companion diagnostic tests for RA therapies. The signature of this agreement marks the start of close collaboration between the two organizations because TcLand Expression's researchers will cooperate with the joint Inserm/University of Rouen U905 "Physiopathology and Biotherapy of Inflammatory and Autoimmune Disease" research unit (headed by Professor Olivier Boyer).

"This agreement is much more than a simple licensing deal because it means that our R&D division will collaborate closely with Inserm researchers on the design of companion diagnostics for treatment of RA - a severe, disabling disease which affects some 70 million people worldwide!", commented TcLand Expression CEO Alain Huriez. "Our company has forged a number of strategic collaborations for the development of new biomarkers in this disease area - not only with the Inserm but also with the Vall d'Hebron University Hospital Research Institute in Spain and the Lyons Public Hospitals Group in France", he concluded.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures